Bristol-Myers Squibb (BMS) will expand access to its HIV drug Reyataz (atazanavir) in Brazil, according to a BMS statement. The pharmaceutical company has signed a technology transfer agreement with the Brazilian Ministry of Health, which will enable the Brazilian government to locally manufacture and distribute 200 mg and 300 mg capsules of Reyataz.
To read the BMS statement, click here.